CGW

China Automotive Intelligent Door Research Report 2023 Featuring 17 Intelligent Door System Suppliers

Retrieved on: 
Thursday, February 15, 2024
BCM, Light, HiPhi, AI, CGW, PEPS, Intelligence, SOA, SenseTime, Composer, 3D, Noise, Original equipment manufacturer, XPeng P7, HiPhi Z, IM L7, DOW, NIO, Travel, Communication, ArcSoft, Human, IVI, Leapmotor C11, NIO ET5, Cerence, BRAIN, Brose, PWM, Environment, Face, Software, Instrumentation

DUBLIN, Feb. 15, 2024 /PRNewswire/ -- The "China Intelligent Door Market Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, Feb. 15, 2024 /PRNewswire/ -- The "China Intelligent Door Market Research Report, 2023" report has been added to ResearchAndMarkets.com's offering.
  • China Intelligent Door Market Research Report, 2023 analyzes and studies the features, market status, OEMs' layout, suppliers' layout, and development trends of intelligent doors in China.
  • In terms of marketization degree, the intelligent door functions that have found wide application in vehicles include APP-controlled doors, door open warning (DOW), hidden electric door handles, frameless doors, electric suction doors, automatic door opening and closing, etc.
  • For instance, the next-generation door system electronic control unit developed by Brose integrates all door functions from window regulators and automatic door opening/closing to collision detection.

China Automotive Intelligent Door Research Report 2023: With Domain Controller Architecture, OEMs Connect Doors with Cameras, Radars, Ambient Lights to Create Intelligent Entry and Exit Experiences - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 15, 2024
Automotive Manufacturing, Manufacturing, Vehicle Technology, Aftermarket, Audio, Video, Autonomous Driving, Vehicles, Automotive, Other Technology, EV, Electric Vehicles, Software, Hardware, Technology, Alternative Vehicles, Fuels, Other Manufacturing, Other Automotive, General Automotive, Engineering, Performance & Special Interest, BCM, Light, HiPhi, AI, CGW, PEPS, Intelligence, SOA, SenseTime, Composer, 3D, Noise, Original equipment manufacturer, XPeng P7, HiPhi Z, IM L7, DOW, NIO, Travel, Communication, ArcSoft, Human, IVI, Leapmotor C11, NIO ET5, Cerence, BRAIN, Brose, PWM, Environment, Face, Instrumentation

China Intelligent Door Market Research Report, 2023 analyzes and studies the features, market status, OEMs' layout, suppliers' layout, and development trends of intelligent doors in China.

Key Points: 
  • China Intelligent Door Market Research Report, 2023 analyzes and studies the features, market status, OEMs' layout, suppliers' layout, and development trends of intelligent doors in China.
  • In terms of marketization degree, the intelligent door functions that have found wide application in vehicles include APP-controlled doors, door open warning (DOW), hidden electric door handles, frameless doors, electric suction doors, automatic door opening and closing, etc.
  • APP-controlled doors boast the highest installation rate, higher than 30% as of July 2023, followed by DOW with over 10%.
  • With domain controller architecture, OEMs can connect doors with cameras, radars, ambient lights, etc.

Velsera Launches Faster, Smarter Clinical Interpretation Workflows for Analyzing and Reporting on Genetic Sequence Data

Retrieved on: 
Wednesday, November 15, 2023
Data Management, Biotechnology, Technology, Health, General Health, Oncology, Health Technology, Research, Software, Genetics, Science, Complement, Annual general meeting, Weill Cornell Medicine, Patient, Memory, Workflow, CGW, Doctor of Philosophy, NGS, Biomarker, AMP, Microsatellite instability, Medical imaging, MD

Velsera's latest offering combines expertly curated evidence, dynamic interpretations and adaptive behavior to drive significantly shorter signout times and smarter clinical interpretation.

Key Points: 
  • Velsera's latest offering combines expertly curated evidence, dynamic interpretations and adaptive behavior to drive significantly shorter signout times and smarter clinical interpretation.
  • Memory of Biomarker Reporting Decisions: Velsera's CGW can now remember and reuse biomarker reporting decisions, including interpretations and reported treatment options.
  • CGW is an all-in-one analysis and reporting tool for clinical NGS data, based on an industry-leading knowledgebase, robust clinical reporting and tailored lab services.
  • “High Quality, Automated Oncology ‘Omics Reporting with Velsera’s Knowledgebase”, presented by Will Moller, director of product management at Velsera.

Velsera and Solaris Health Partner to Expand Access to Genetic Testing that Helps Urology Patients Understand Cancer Risks

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Practice Management, Oncology, General Health, Health, Health Technology, Genetics, Other Health, Patient, DSM-IV codes, Genetic testing, Physician, CGW, Doctor of Philosophy, Trust, NGS, Risk, Partnership, Cancer, Diagnosis, DNA, Pharmaceutical industry, MD

Solaris Health is proud that its affiliated urology practices are the first to afford their patients the ability to receive in-house genetic testing.

Key Points: 
  • Solaris Health is proud that its affiliated urology practices are the first to afford their patients the ability to receive in-house genetic testing.
  • The partnership with Velsera, which provided critical technology, services and expertise, has furthered the goal to expand access to this guideline-based testing across the nation.
  • Inherited cancer testing looks for DNA variants inherited from an individual’s parents that would predispose them to develop certain kinds of cancer.
  • The partnership with Velsera has greatly accelerated the ability of affiliated practices to offer this vital genetic testing to patients," said Solaris Chairman Deepak Kapoor, MD.

VicOne Collaboration with NXP Semiconductors and Inventec Yields Integrated Real-Time Cybersecurity Solution for SDVs

Retrieved on: 
Tuesday, June 13, 2023
Technology, Semiconductor, Automotive, Vehicle Technology, Security, Automotive Manufacturing, Manufacturing, Other Automotive, Software, Partnership, Electronics, ISO, Original equipment manufacturer, EVP, CGW, SDV, Engineering, NXP, Risk management, Inventec

VicOne, an automotive cybersecurity solutions leader, announced today a collaboration with NXP® Semiconductors and Inventec that has led to an integrated, real-time cybersecurity solution for emerging software-defined vehicles (SDVs).

Key Points: 
  • VicOne, an automotive cybersecurity solutions leader, announced today a collaboration with NXP® Semiconductors and Inventec that has led to an integrated, real-time cybersecurity solution for emerging software-defined vehicles (SDVs).
  • Powered by NXP's S32G vehicle network processor, Inventec's vehicle Central Gateway (CGW) is integrated with VicOne's cybersecurity software solutions.
  • Plus, the integration aligns strongly with the automotive industry’s emerging compliance requirements, such as the ISO/SAE 21434 standard for cybersecurity engineering.
  • The event, for which VicOne is one of the sponsors, brings together more than 1,000 engineers for two days of NXP training, networking, solution demonstrations and presentations from industry leaders.

Arima Genomics and Velsera Announce Partnership to Enable Broad Adoption of Arima Gene Fusion Test in Clinical Laboratories

Retrieved on: 
Tuesday, February 7, 2023
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Research, Software, Genetics, Science, Strategic management, Library, Laboratory, Genomics, Workflow, Fusion, CGW, NGS, Data analysis, RNA, Senior, Arima, Neoplasm, Vaccine, Pierian Spring

Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.

Key Points: 
  • Under the terms of the agreement, Velsera will integrate Arima Genomics’ targeted next-generation sequencing (NGS) testing pipelines into the Pierian Clinical Genomics Workspace (CGW), the leading cloud-based platform that provides clinical labs more streamlined and accurate NGS data analysis, interpretation, and reporting.
  • The combined solution will enable clinical laboratories to more easily implement sample-to-answer Arima gene fusion testing, helping them identify gene fusions and other structural variants.
  • “Adopting new NGS technologies and instituting new protocols for clinical genomic interpretation and reporting is time-consuming and challenging,” said Chris Roberts, Senior Vice President, Corporate Strategy at Arima Genomics.
  • “We look forward to integrating Arima Genomics’ gene fusion detection technology into our Clinical Genomics Workspace platform.

PreCheck Health Services Showcases New Hereditary and Somatic Cancer Testing Capabilities at the A4M World Congress with Support From Pierian

Retrieved on: 
Tuesday, November 29, 2022
Sickle Cell Anemia, a Molecular Disease, Hospital Insurance and Diagnostic Services Act, Public health, DNA sequencing, Genomics, Multimedia, Machine learning, Health, Physician, Patient, CGW, Laboratory, Cancer, Classification, TSA PreCheck, Somatic mutation, Precision medicine, NGS, CAP, Algorithm, Medicine, Medical imaging, Pharmaceutical industry, Pierian Spring, Illumina

By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.

Key Points: 
  • By supporting hereditary cancer testing, patients can now benefit from the advantages of NGS to enable more precise cancer diagnosis.
  • Their first two NGS offerings are based on Illumina's TruSight Hereditary Cancer and TruSight Oncology 500 panels.
  • PreCheck Health Services will be exhibiting at the 30th annual A4M World Congress from December 9th to 11th in Las Vegas, NV at booth #3102.
  • PreCheck Health Services will be showcasing their newly validated cancer panels and offering the attendees detailed sample reports from the Pierian Clinical Genomics Workspace (CGW).

Citi Global Wealth Investments Releases Outlook 2022: The Expansion Will Endure: Seeking Sustained Returns

Retrieved on: 
Thursday, December 9, 2021
Banking, Professional Services, Finance, Environment, Face, Citi Private Bank, Growth, CGW, Science and technology in Asia, COVID, Investment, Life, Time, Citigroup, Capital market, Bank, Financial services

Citi Global Wealth Investments today released its Outlook 2022 report, titled The expansion will endure: Seeking sustained returns .

Key Points: 
  • Citi Global Wealth Investments today released its Outlook 2022 report, titled The expansion will endure: Seeking sustained returns .
  • Announced in January 2021, Citi Global Wealth (CGW) is comprised of the wealth management businesses of Citi Private Bank and Citis Global Consumer Bank.
  • The unified management and delivery of CGWs wealth strategy represents a further commitment by Citi to become a leading global wealth business.
  • Citi Global Wealth Investments (CGWI) is comprised of the Investments and Capital Markets capabilities of Citi Private Bank, Citi Personal Wealth Management and International Personal Bank U.S.
    Citi, the leading global bank, has approximately 200 million customer accounts and does business in more than 160 countries and jurisdictions.

PierianDx Partners with Florida Cancer Specialists & Research Institute to Advance Cancer Care

Retrieved on: 
Thursday, October 7, 2021
Software, Biotechnology, Pharmaceutical, Oncology, Health, Medical Devices, Technology, Genetics, Lists of diseases, FCS, Genomics, Data analysis, CGW, Physician, University of Florida Cancer and Genetics Research Complex, Illumina, Cancer, Precision medicine, Population, Adoption, Lymphatic system, Laboratory, Lymph, CEO, Therapy, Partnership, Invitae, Patient, Clinical trial, NGS, Technology, Medical imaging, Pharmaceutical industry

By localizing genomic testing, FCS patients will benefit from more direct access to testing within the context of care.

Key Points: 
  • By localizing genomic testing, FCS patients will benefit from more direct access to testing within the context of care.
  • The genomic test results at Florida Cancer Specialists will be delivered via a customizable report generated by the PierianDx CGW.
  • According to Florida Cancer Specialists CEO Nathan H. Walcker, We see tremendous clinical and strategic value to performing this very important testing in-house.
  • We are thrilled to provide our best-in-class bioinformatics and knowledge platform to support personalized, community-based cancer care, states Mark McDonough, CEO of PierianDx.